The precore/core gene of hepatitis B virus directs the synthesis of two polypeptides, the 21-kilodalton subunit (p21c) forming the viral nucleocapsid (serologically defined as core antigen [HBcAg]) and a secreted processed protein (pl7e, serologically defined as HBe antigen [HBeAg]). Although most of their primary amino acid sequences are identical, HBcAg and HBeAg display different antigenic properties that are widely used in hepatitis B virus diagnosis. To locate and to characterize the corresponding determinants, segments of the core gene were expressed in Escherichia coli and probed with a panel of polyclonal or monoclonal antibodies in radioimmunoassays or enzyme-linked immunosorbent assays, Western blots, and competition assays. Three distinct major determinants were characterized. The single conformational determinant responsible for HBc antigenicity in the assembled core (HBc) and a linear HBe-related determinant (HBel) were both mapped to an overlapping hydrophilic sequence around amino acid 80; a second HBe determinant (HBe2) was assigned to a location in the vicinity of amino acid 138 but found to require for its antigenicity the intramolecular participation of the extended sequence between amino acids 10 and 140. It is postulated that HBcAg and HBeAg share common basic three-dimensional structure exposing the common linear determinant HBel but that they differ in the presentation of two conformational determinants that are either introduced (HBc) or masked (HBe2) in the assembled core. The simultaneous presentation of HBel and HBc, two distinctly different antigenic determinants with overlapping amino acid sequences, is interpreted to indicate the presence of slightly differently folded, stable conformational states of p21c in the hepatitis B virus nucleocapsid.
The precore/core gene of hepatitis B virus directs the synthesis of two polypeptides, the 21-kilodalton subunit (p21c) forming the viral nucleocapsid (serologically defined as core antigen [HBcAg] ) and a secreted processed protein (pl7e, serologically defined as HBe antigen [HBeAg] ). Although most of their primary amino acid sequences are identical, HBcAg and HBeAg display different antigenic properties that are widely used in hepatitis B virus diagnosis. To locate and to characterize the corresponding determinants, segments of the core gene were expressed in Escherichia coli and probed with a panel of polyclonal or monoclonal antibodies in radioimmunoassays or enzyme-linked immunosorbent assays, Western blots, and competition assays. Three distinct major determinants were characterized. The single conformational determinant responsible for HBc antigenicity in the assembled core (HBc) and a linear HBe-related determinant (HBel) were both mapped to an overlapping hydrophilic sequence around amino acid 80; a second HBe determinant (HBe2) was assigned to a location in the vicinity of amino acid 138 but found to require for its antigenicity the intramolecular participation of the extended sequence between amino acids 10 and 140. It is postulated that HBcAg and HBeAg share common basic three-dimensional structure exposing the common linear determinant HBel but that they differ in the presentation of two conformational determinants that are either introduced (HBc) or masked (HBe2) in the assembled core. The simultaneous presentation of HBel and HBc, two distinctly different antigenic determinants with overlapping amino acid sequences, is interpreted to indicate the presence of slightly differently folded, stable conformational states of p21c in the hepatitis B virus nucleocapsid.
Hepatitis B virus (HBV) is a small DNA virus which consists of a lipid envelope containing viral surface antigens and an inner core containing the viral DNA genome, a DNA polymerase, and a protein covalently linked to the 5' end of the DNA minus strand (for recent reviews, see references 2 and 11). The viral core has a polyhedral structure composed of identical subunits of 21 kilodaltons (kDa); it is serologically defined as core antigen (HBcAg). HBcAg has been proposed to be related to HBe antigen (HBeAg), a second HBV-induced antigen, on the basis of the fact that HBcAg can be converted into HBeAg upon denaturation and/or limited proteolysis (19, 36) . In nature, however, HBeAg is always present in a nonparticulate state in the serum of HBV-infected individuals, whereas the polymeric HBcAg occurs only in the enveloped virus or inside HBV-infected hepatocytes.
During convalescence, antibodies to HBcAg and HBeAg, termed anti-HBc and anti-HBe, respectively, are detected along with antibodies against the viral surface antigen. These antibodies are important serological markers in defining the status of HBV infection and therefore, together with their corresponding antigens, have been subjects of intense research and use. Nevertheless, a satisfactory distinction between HBcAg and HBeAg has become possible only with the introduction of monoclonal antibodies specific for either antigen. These antibodies have been grouped into two classes of anti-HBe monoclonal antibodies and one class of Animals, 7400 Tubingen, Federal Republic of Germany.
anti-HBc monoclonal antibodies (9, 16, 43) . However, a comparable physical separation of the corresponding three antigenic determinants has not yet been achieved.
By using recombinant DNA technology, the basic relationship of HBcAg and HBeAg as revealed by structural and serological analysis has been complemented by an elucidation of the basic mechanism of their differential biosynthesis (12, 18, 20, 26, 31) . Accordingly, these two major core gene (C gene) products are produced by alternate translation from two different start codons located at the 5' end of the preC or C open reading frame. Usage of the preC start in a "preC mRNA" results in a 25-kDa precore/core precursor protein (p25) which is secreted and concomitantly processed at either end to result in a 17-kDa HBeAg. In the slightly shorter C-mRNA, which lacks the preC start codon, translation leads directly to the p21c core protein (HBcAg), which self-assembles in the cytoplasm to the nucleocapsid containing its own mRNA, which then serves as the template for reverse transcription during core maturation. Thus, the principal features of the mechanism that directs two structurally largely overlapping, but antigenically markedly differing, polypeptides into separate cellular compartments are now well established, and it is generally accepted that the 17-kDa HBeAg is produced in vivo not by denaturation or degradation of the 21-kDa core antigen but instead by a distinct secretory mechanism involving the precore signal sequence. However, other aspects, such as the processing of the HBeAg precursor, the folding and potential modifications of the different proteins, their domain structure, and consequently the structures exposed and recognized by the humoral immune system, remain largely unknown.
In this report, we describe experiments aimed at dissecting the two C gene-encoded antigens and their antigenic determinants by using recombinant DNA 44) .
Antigens and antibodies. Protein extracts from HBV-positive and HBV-negative liver tissue used for the experiments documented in Tables 1 and 5 were prepared as described previously (46) . Purified HBcAg, as used for the anti-HBc assays (see Table 5 ), was prepared by the method of Summers and Mason (35) , with some changes. After the nuclei and cellular debris were removed, the supernatant was pelleted by passage through a 30% sucrose cushion by centrifugation at 25,000 rpm for 8 h at 4°C in a Beckman SW27 rotor. The pellet was resuspended in extraction buffer and again sedimented through a 15 to 30% linear sucrose gradient. Recombinant HBcAg was a gift from Paul Wingfield, BIOGEN S.A., Geneva, Switzerland. Natural HBeAg was purified from serum as described previously (37) . The differentiation of soluble and particulate antigens (see Fig.  1B Tables 2 and 3 were labeled with horseradish peroxidase by the method of Ishikawa et al. (17) .
The enzyme-linked immunosorbent assay (ELISA) with peptides or with fusion protein c74-89 as antigen was done as described previously (28 Table 2 ) was detected by incubating the monoclonal antibodies in the HBcAg-coated wells for 1 h at 37°C. The bound monoclonal antibodies were detected by using anti-mouse immunoglobulin G (IgG) peroxidase conjugates as described previously (28) .
Western blots. Western blots were performed as described previously (46) . In order to study the antigenicity of fusion proteins, E. coli extracts containing 1 to 2 jig of fusion protein were analyzed by Western blotting by using 1 ml of the 1251I-labeled antibodies for detection. To test fusion proteins with unlabeled monoclonal antibodies, the latter were used at a concentration of 1 ,ig/ml in 2% bovine serum albumin-1 x PBS-0.05% Nonidet P-40. After repeatedly rinsing the filters with 1 x PBS-0.05% Nonidet P-40, the bound antibodies were detected with 125I-labeled anti-mouse IgG F(ab')2 fragments (Amersham Buchler, Braunschweig, Federal Republic of Germany). To analyze antigens from patient sera, 10 ,ud of total serum was boiled with 20 ,ul of sample buffer and subsequently separated on a 15% polyacrylamide gel. HBc gene-encoded proteins were detected with the rabbit antiserum c110-183.
Purification of the fusion protein C74-89. The MS2 fusion protein c74-89 was purified from a 200-ml E. coli culture by the urea extraction technique described previously (34) and by exclusion chromatography on a column 3 cm in diameter and 340 ml in volume equilibrated with PBS-7 M urea running at 14 ml/h. The fractions were characterized by ELISA by using a serum against peptide c76-89; the purity of the positive fractions was tested by sodium dodecyl sulfatepolyacrylamide gel electrophoresis.
Transfection and analysis of core gene products. Plasmid pSHH2.1 containing a tandem repeat HBV genome of HBV subtype ayw (6) has been described by Cattaneo et al. (4) . Plasmid pAOl-HBV of subtype adw (8) was obtained from J. Summers via P. H. Hofschneider; it has been described by Wang et al. (42) as being essentially identical (by restriction mapping) to the adw isolate sequenced previously (40) . The plasmids were cleaved with EcoRI, and the released HBV DNA was circularized and transfected into HepG2 cells as described recently (5) . A 10-ml portion of cell culture supernatant, positive for HBeAg as determined by the HBe/HBc RIA, was clarified by centrifugation and freed from virus by ultracentrifugation and then subjected to immunoprecipitation by using a combination of the sera c78-167 and c110-183 (46) and serum 28a/6 preadsorbed to protein A-Sepharose (Pharmacia, Uppsala, Sweden). This protein A-Sepharose was then shaken gently with the cell culture supernatant for 12 h at 4°C. After repeated washing steps, the antigens and antibodies bound to the protein A-Sepharose were boiled in sample buffer, separated on a 15% polyacrylamide gel, and analyzed by Western blotting as described previously by using serum c110-183 for detection (46) .
RESULTS
Characterization of HBeAg polypeptides. Because the reports on the size and homogeneity of HBeAg-related proteins still disagree (e.g., see references 3 and 37), we started out to characterize on Western blots the HBcAg/HBeAg polypeptides present in sera from HBV-infected patients ( Fig. 1 ). By using a polyclonal antiserum raised against the denatured core-fusion protein (c110-183; Fig. 2 ), the major C-gene product, p21c, was readily detected in all viruscontaining (HBV-DNA positive) sera, as expected on the basis of its function as the viral nucleocapsid. In addition, a protein of about 17 (37) .
Interestingly, in some of our HBeAg-positive serum samples additional nonparticulate HBcAg/HBeAg proteins were observed which migrated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as distinct bands between p21c and pl7e (Fig. 1B) . In such sera, the 17-kDa band was significantly reduced or absent, suggesting that the new proteins were substituting for the pl7e species. Similarly, heterogeneous and larger HBeAg species have also been reported by others (3, 20, 37) . A serological analysis of the proteins and a restriction analysis of the viral genomes present in our serum samples revealed that these genomes were related to HBV subtype adw. In this subtype, the core protein sequence, as deduced from its DNA sequence (40) , differs from that found in the three other HBV subtypes (including subtype ayw, which was used in this study) by a two-amino-acid insert that changes the sequence near the major processing site at amino acid 149 from T-T-V-V-R-R-R-G (27, 37) 
To determine whether this alteration had caused a subtype-specific size increase of the HBeAg protein, we produced HBeAg by transient expression of cloned HBV DNA of either subtype in hepatoma cells (5) . As shown in Fig. 2C Expression of the HBc gene in E. coli and preparation of stably expressed deletion mutants. To obtain defined fragments of the C gene products in large amounts and free from any other contaminating core protein fragments, we expressed segments of the C gene in E. coli fused to the first 99 codons of the RNA replicase gene of bacteriophage MS2 (29, 34 ; see Materials and Methods). As a parent for the desired variants, plasmid pc2-183 was constructed; it encodes, fused to the MS2 leader, the entire p21c polypeptide sequence, except for the initiating methionine codon. From this construct, a large number of terminal deletion mutants was obtained by exonuclease digestion either from the EcoRI site joining the 5' end of the C gene to the MS2 leader or at its 3' end from the unique AvaI site in position 533 (Fig. 2) . In the latter mutants, the core protein sequences are followed at their carboxy termini by short sequences of 13, 18, or 28 amino acids (Fig. 2) specified by the three reading frames of the vector sequence following the HBV DNA insert (34 
thesis).
These results indicate that most of the core protein sequence is necessary to present the minimum of two antigenic determinants required in the bivalent assays described above.
The data from the bivalent RIAs were complemented by monovalent Western blots in which the carboxy-terminally deleted MS2/core fusions were probed with the labeled antibodies from either RIA (Fig. 3) interfered only with the HBe RIA and therefore compete with either monoclonal antibody e-1 or monoclonal antibody e-2 and recognize HBeAg.
Two of these HBe-specific monoclonal antibodies, c-1 and c-15, yielded equivocal results. Antibody c-1 showed only a 50% inhibition in the HBe RIA. However, by using the MS2 fusion protein c2-141 as a "recombinant HBeAg," residual binding was reduced from 50% to 12% for monoclonal antibody c-1 (Table 2) , confirming specific competition. The second monoclonal antibody, c-15, being characterized clearly by a strong competition reaction in the HBe RIA, competed also to some extent in the HBc-specific ELISA and also bound to core particles (Table 2) From the HBc-specific monoclonal antibodies, monoclonal antibody c-14, which had been classified before as being HBc specific (43) and which had therefore been included as a reference, exhibited much less, although still significant, competition in the HBc/e RIA than did the monoclonal antibodies c-205, c-275, and c-312. Since similar IgG concentrations were employed (data not shown), this poor reaction appears to be due to a lower binding constant of c-14. Alternatively, because the HBc determinant overlaps with determinant HBel (see below), these differences in competition could also reflect differences in the capacity of the anti-HBel monoclonal antibodies to interfere with the binding of anti-e-1 antibodies recognizing epitopes overlapping with the HBc determinant.
Finally, the monoclonal antibodies classified above as HBc specific (c-14, c-205, c-275, and c-312) were also characterized by their mutual cross-competition in an ELISA (Table 3) ; enzyme-linked monoclonal antibodies c-205 and c-312 were also found to be blocked by more than 98% by 30 different randomly chosen anti-HBc-positive human sera (Table 3 ). In a complementary experiment, the binding to HBcAg of peroxidase-labeled polyclonal anti-c antibodies was blocked by more than 85% by monoclonal antibodies c-205 and c-312 (data not shown). Taken together, these data demonstrate that a single dominant HBc determinant is recognized by the human humoral immune system and that this site is also detected by the four mouse monoclonal antibodies selected for our study. Fine mapping of epitopes recognized by monoclonal antibodies in Western blots. With a set of well-characterized monoclonal antibodies at hand, the fine mapping of the corresponding determinants was continued in Western blots by using the complete panel of shortened C gene products described above (Fig. 2) . The results obtained in these experiments are exemplified in Fig. 3 and 4 and summarized in Table 4 . They are discussed below separately for each determinant in context with the results from the RIAs, along with some further experiments to be described later.
Determinant HBc. In general, anti-HBc antibodies present in human serum recognize the protein p21c only if it is presented in the form of the core particle. Surprisingly, of the four HBc-specific monoclonal antibodies described c4-183 c_c2-141 c2-138
above (c-14, c-205, c-275, and c-312), two (c-205 and c-312) also reacted with C gene products in the form of the less well-structured MS2 fusions (Fig. 4 ) and thus allowed a deletion mapping of the determinant. Large fusions such as protein c2-141 were recognized quite well, and monoclonal antibody c-312 reacted equally well even with the much further shortened proteins c2-89, c2-83, and c74-90 (Fig. 4,  right panel) . Monoclonal antibody c-205 reacted strongly with protein c2-89 also but only very poorly with protein c2-83 and not at all with protein c74-89 (Fig. 4) . Thus, monoclonal antibody c-312 appears to recognize an epitope contained in the sequence (74) V-N-L-E-D-P-A-S-R-D (83), whereas the epitope for monoclonal antibody c-205 appears to extend further toward the carboxy terminus. The Western blots presented in Fig. 4 characterize also the epitope recognized by the third HBc-specific monoclonal antibody, c-275, by showing that it reacted to a similar extent, although quite poorly, with proteins c2-141 and c2-83 but not with protein c74-89. Thus, the conformational epitope recognized by this third antibody also overlaps with the amino acid sequences recognized by c-205 and c-312. No signal was obtained with the apparently fully conformationdependent antibody c-14, which had, however, been characterized as being closely related to monoclonal antibody c-275 in the competition studies described in Table 3 .
In summary, our data demonstrate that a single dominant HBc determinant induces a numerous population of antiHBc antibodies which range from highly conformationdependent antibodies (such as c-14) to antibodies that also recognize short linear subsequences (such as c-312). All three monoclonal epitopes detected were located between amino acids 74 and 89, but only one monoclonal antibody (c-312) reacted strongly with fusion proteins containing this subsequence; none of the human polyclonal antibodies did. From these data we conclude that the HBc epitopes recognized by human anti-HBc antisera are predominantly conformational.
Determinant HBel. In immunoblots, HBc/HBe polyclonal antibodies recognized a series of carboxy-terminal deletions, including MS2/core fusions as short as protein c2-89 ( Fig. 3 and Table 4 Table 2 ). Monoclonal antibody c-1 is HBeAg specific. The preS-specific antibody s-1 was used as a control. The molecular masses given in the center were determined by using 14C-labeled proteins. (Fig. 5B ). Essentially the same result was obtained by using a synthetic tetradecapeptide containing amino acid c76-89, which reacted specifically with a human serum highly positive for both anti-HBe and anti-HBc but not with a human serum which has a high anti-HBc titer (1:10,000) but only a negligible anti-HBe titer (1:10) (Fig. 5A) . Neither antigen reacted with sera from uninfected controls.
From these experiments, we conclude first that the HBel determinant resides in the amino acid sequence (76) L-E-D-P-A-S-R-D-L-V-V-S-Y (89) and second that it is a primarily linear determinant. These conclusions are supported further by the results obtained in experiments in which the recognition of natural HBeAg by the monoclonal antibody e-1 in the solid phase of the Sorin HBe assay was blocked specifically by an excess of the synthetic tetradecapeptide, demonstrating that the HBel determinant was recognized by the solid-phase monoclonal antibody (e-1) in the Sorin assay (Salfeld, Ph.D. thesis).
Determinant HBe2. Initially defined to the region around amino acids 130 to 140 by its reaction with monoclonal antibody e-2 in the HBe RIA and in Western blots (Table 1, Fig. 3 ), the HBe2 determinant was characterized further by using two of the additional HBe-specific monoclonal antibodies (c-1 and c-15). These antibodies had been determined to be related to e-2 by their cross-competition in the second step of the Sorin HBe assay (data not shown). As demonstrated in Fig. 4 for c-1, these monoclonal antibodies reacted equally well in Western blots with the three MS2 fusions, c2-138, c2-141, and c4-183, which had been recognized differentially by monoclonal antibody e-2 (Fig. 3, Table 1 ). These results indicate that the HBe2 epitopes corresponding to monoclonal antibodies e-2, c-1, and c-15 are part of a more extended determinant ending near amino acid 138. This notion is also supported by the rather weak competition of all three of the monoclonal antibodies with the labeled polyclonal immunoglobulins recognizing this determinant in the HBc/e RIA (Salfeld, Ph.D. thesis) and also by the residual antigenicity of about 30% displayed by protein c2-138 in this polyclonal assay ( Table 1 ).
The amino-terminal limit of the HBe2 determinant could not be defined as well, since all anti-HBe antibodies used in our study reacted only with short N-terminal deletions, such as c4-183 (Fig. 4) , but did not react in either sandwich RIA with C gene products N-terminally deleted to amino acid 12 FIG. 5 . ELISA of peptide c76-89 and fusion protein c74-89 using sera from anti-HBe-or anti-HBc-positive patients. (A) The peptide c76-89 was analyzed by using different patient sera positive for anti-HBc (A) or anti-HBe (0) or by using a control serum (*). A 10-,ug portion of peptide was used in each experiment. The dilution of the human sera, as well as the ELISA readings, is indicated. (B) The fusion protein c74-89 (0.05 ,ug of purified fusion protein per well) was analyzed by using two anti-HBe-positive patient sera (O and A) and a control serum (*). The serum dilution used, as well as the ELISA readings, is indicated. a Competing antibodies were present during binding and detection. The assay was done as suggested by the manufacturer. The polyclonal antibodies were used undiluted; the monoclonal antibodies were used as described in the caption to Table 2 . Anti-c2-48 serum is described in Materials and Methods; for characterization of monoclonal antibody c-18, see Tables 2 and 4. b The standard protocol was modified as follows. The solid-phase antibody e-1 was incubated with 200 ,ul of HBeAg for 20 h at room temperature; after three washing steps, the solid phase was incubated with 200 p.l of undiluted serum at 45'C. After repeated washing steps, the bound HBe antigen was detected by incubation with 100 ,u1 of the 1251I-labeled monoclonal antibody e-2 and an additional 100 p.l of the serum used for the competition study.
or beyond (Table 1) . Similarly, HBe antigenicity was found to be drastically reduced in a core gene product that had been fused at amino acid 12 to the first eight amino acids of the E. coli P-galactosidase (33) (S. Stahl, personal communication, 1984). Proteins c78-167 and c94-183 also did not react in Western blots with polyclonal anti-c/e antibodies or with HBe2-specific monoclonal antibodies (Salfeld, Ph.D. thesis). Further evidence for a contribution of N-terminal amino acid sequences to the HBe2 determinant is provided by the experiments described in Table 5 . Here, a rabbit serum recognizing the subsequence c2-48 (see Materials and Methods) or monoclonal antibody c-18 (shown to recognize an epitope contained in the subsequence c2-63 [ Table 4 ]) was shown to interfere with the binding of monoclonal antibody e-2 to serum-derived HBeAg, while no inhibition was observed with the appropriate rabbit preimmune serum or with a monoclonal antibody of different specificity.
Taken together, these data provide substantial evidence that the HBe2 determinant requires for its correct conformation not only amino acid sequences ending around amino acid 138 but also the direct or indirect intramolecular participation of amino-terminal amino acid sequences present in both p21c and pl7e polypeptides. This intramolecular interaction must recur after protein denaturation since determinant HBe2 is detected in Western blots which inv-olve a denaturation step.
The HBel determinant is exposed on the core particle. The negative result obtained in the bivalent monoclonal antibody HBe RIA with HBcAg as an antigen (Table 1) did not exclude the possibility of a monovalent interaction of antiHBe antibodies with p2lc subunits assembled in core particles. This was tested with the reagents from both commercial assays in cross-combination, i.e., the polyclonal anti-c/e serum or monoclonal antibody e-1 as solid phase, and for detection the radiolabeled monoclonal antibody e-2 or the polyclonal anti-c/e antibodies (Table 6 ). In the heterologous combinations, core particles were found to be bound to the e-1 monoclonal antibody on the solid phase of the Sorin kit and were detected by the polyclonal anti-c/e serum. In HBeAg that have so far been attributed primarily to the defined structural features of the p21c polypeptide in being the constituent of a regularly structured viral nucleocapsid. In contrast, the HBeAg was considered to be a more or less nonstructured protein which had lost its HBc antigenicity upon denaturation and/or limited proteolytic cleavage, thereby exposing additional, different determinants. A simplified scheme combining the principal structural and antigenic features of the two antigens as revealed by our data is presented in Fig. 6 in the context of their relationship to the primary precore/core amino acid sequence. While the well-characterized core antigen (HBcAg, p21c) comprises all 183 amino acids encoded by the core gene (33, 44) , recent in vitro studies suggest that the 17-kDa HBeAg polypeptide comprises the 159 amino acids from the serine at position -10 (the site for signal cleavage) during HBeAg secretion in vitro or in Xenopus oocytes (12) (D. Standring, personal communication) up to the biochemically determined Cterminal threonine at position 149 (37) . This latter end most likely marks the processing site in the sequence (146) T-T-V-V R-R-R-G (153) that is selectively cleaved during HBeAg secretion in vivo. A similar sequence (T-T-V-V-Y-G-R-R-R) appears to be cleaved in the analogous reaction during secretion of duck HBeAg from duck HBV-infected cells (31) . As demonstrated here by analyzing HBeAg produced from HBV subtype adw, alteration of the proposed HBcAg-processing site to T-T-V-V-R-D-S-R-R-G interferes with its cleavage and results in a series of significantly larger HBeAg variants by cleavage at one of three secondary cleavage sites (Fig. 6A ) located near the other three carboxyterminal arginine clusters (starting at positions 157, 164, and 172 and predicting HBeAg adw molecules of 168, 182, and 189 amino acids, respectively). Thus, HBeAg maturation most likely involves a protease(s) whose specificity is different from those of the aspartate proteases known to be involved in the processing of the gag proteins or the gag-pol fusions of retroviruses and predicted by sequence homology to also be encoded in the HBV core gene (22) .
It should be noted that non-carboxy-terminally processed precore/core gene products (predicted to encompass the 193 amino acids from positions -10 to 183 and designated p22.3, p22, or p23) have been observed only in cell-free translation systems (3, 12, 44) (Fig. 6A) . Amino acid sequences at the boundaries of the domain appear to be particularly important, as indicated by their conservation between HBV serotypes and within the mammalian viruses (Fig. 6C) .
It is also of note that the HBeAg domain defined above appears to be closely related to the domain required for core "cores" upon synthesis in E. coli, as has been shown in detailed studies for the full-length core protein (7, 22a, 33) . Unpublished experiments by S. Stahl (personal communication, 1984) and H. Muller (Diplomarbeit, University of Heidelberg, 1986) have demonstrated that core polypeptides lacking as many as 39 C-terminal amino acids self-assemble into cores, whereas the loss of only a few N-terminal amino acids abolishes this ability (Fig. 6A) . Therefore, it seems likely that HBcAg and HBeAg share a related basic threedimensional structure which requires for its correct folding that the core polypeptide chain be essentially intact between positions 10 and 140. This domain appears to be tightly folded, as indicated by its high resistance to protease digestion (e.g., see reference 12) and to modification by chemical reagents used for radioisotope labeling (our own unpublished observations).
The concept of a common basic HBcAg/HBeAg structure is supported further by our finding that the amino acid sequence around position 80 is exposed and recognized as a major antigenic determinant (HBc and/or HBel) in both HBcAg and HBeAg; a surface location of this sequence is also suggested by its high hydrophilicity (Fig. 6B ) and by its preferential tolerance to naturally occurring mutational amino acid changes in an otherwise well-conserved primary structure (Fig. 6C) and to engineered sequence variations (R. Dalseg and M. Nassal, unpublished data). In addition, determination of the size of HBeAg by gel filtration indicates that the native antigen is a dimer of two pl7e molecules (E. Pfaff, unpublished data); formation of this dimer may well involve subunit contacts very similar to those between p21c subunits in the viral core. Thus, the HBcAg/HBeAg polypeptide chain appears to occur in two major, closely related structural states: in a dimeric, but antigenically monovalent, HBeAg state, exposing two antigenic determinants (the HBe2 determinant and the HBc/HBe1 determinant as HBel only) or in the highly assembled HBcAg state, in which HBe2 is masked and in which additional conformational HBc epitopes are introduced into the exposed HBc/HBe1 determinant.
By mapping the HBeAg/HBcAg determinants, our data also contribute to our knowledge of the HBV nucleocapsid structure. From electron microscopy studies (25) and its size, the 27-nm eicosahedral core particle is generally assumed to possess a T = 3 symmetry involving 180 subunits. These chemically identical p21c subunits appear to be present in at least two, only quasi-equivalent, states, because our data demonstrate the concomitant presentation of HBc and HBel, two distinctly different antigenic determinants involving an overlapping primary sequence (Table 6 and Fig. 6 ). The presence of similar subtle differences in subunit conformation in capsids with T-3 symmetry has been demonstrated by X-ray diffraction analysis for the capsids of small eicosahedral RNA plant viruses such as tomato bushy stunt virus and turnip crinkle virus, whose capsids are built from a single subunit existing in three quasi-equivalent states (14) . These viruses share a closely similar subunit topology, which can be described as an eight-stranded anti-parallel I barrel, with picornaviruses such as poliovirus, whose capsids are composed of three different, but very similarly folded, polypeptide chains (for a review, see reference 30). A low but significant sequence homology between the core protein of an HBV-related animal virus and a capsid protein from a picornavirus has recently been detected (1) and, together with our epitope mapping (J. Salfeld, Ph.D. thesis), has been used as a basis for predicting a picornavirus-like three-dimensional structure for the p21c subunit. Although in its details it is highly speculative, this predicted structural correlation to the I barrel subunit structure found in picornaviruses provides a link between the subunit organizations in the tomato bushy stunt virus/picornavirus and HBV nucleocapsids and thus adds further support to our prediction of different, quasi-equivalent states of p21c subunits in the assembled core.
